Research graph
References from Clinicopathological features and treatment paradigms exploration in advanced ampullary cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Ampullary cancer: an overview
10.14694/edbook_am.2014.34.112 · 2014 · External reference
Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program
10.1002/jso.21374 · 2009 · External reference
The gross anatomy and histology of the gallbladder, extrahepatic bile ducts, Vaterian system, and minor papilla
10.1097/00000478-198902000-00008 · 1989 · External reference
The 2019 WHO classification of tumours of the digestive system
10.1111/his.13975 · 2020 · External reference
Prospective evaluation of EUS versus CT scan for staging of ampullary carcinoma
10.1016/j.gie.2008.11.045 · 2009 · External reference
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2023.0034 · 2023 · External reference
Trends in incidence and management of cancer of the ampulla of Vater
10.3748/wjg.v20.i29.10144 · 2014 · External reference
Adjuvant chemo-radiotherapy in ampullary cancers
10.1016/j.ejso.2004.08.013 · 2005 · External reference
The diagnosis and treatment of ampullary cancer
10.3238/arztebl.m2023.0195 · 2023 · External reference
The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater
10.1097/pas.0000000000000230 · 2014 · External reference
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater
10.1200/jco.2012.46.8868 · 2013 · External reference
Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma
10.1038/bjc.2015.172 · 2015 · External reference
Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma
10.1016/j.jamcollsurg.2014.07.665 · 2014 · External reference
Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma
10.1186/s12967-022-03473-w · 2022 · External reference
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary carcinoma randomized trial
10.1001/jama.2012.7352 · 2012 · External reference
Outcomes of palliative chemotherapy for ampulla of Vater adenocarcinoma: a multicenter cohort study
10.5009/gnl230164 · 2023 · External reference
Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications
10.1309/ajcpctcuqsyi89yt · 2011 · External reference
Ampullary carcinoma--a separate clinical entity
10.1111/his.12324 · 2014 · External reference
The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma
10.1038/s41598-019-49179-w · 2019 · External reference
Ampullary adenocancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2023.0034 · 2025 · External reference
Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study
10.1002/bjs.11555 · 2020 · External reference
Genome-derived ampullary adenocarcinoma classifier and postresection prognostication
10.1001/jamasurg.2024.3588 · 2024 · External reference
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
10.1016/s1470-2045(11)70301-1 · 2012 · External reference
A randomised phase II study of oxaliplatin/fluorouracil (mFOLFOX) versus irinotecan/fluorouracil (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy
10.1016/j.ejca.2021.06.019 · 2021 · External reference
Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer
10.1159/000159624 · 2008 · External reference
Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater
10.1620/tjem.231.21 · 2013 · External reference
Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater
10.1177/030089161309900203 · 2013 · External reference
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater
10.1007/s12032-009-9351-4 · 2010 · External reference
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy
10.1093/jjco/hyt237 · 2014 · External reference
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
10.1200/jco.2008.19.7145 · 2009 · External reference
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
10.1056/nejmoa0908721 · 2010 · External reference
Adjuvant chemotherapy for resected ampulla of Vater carcinoma: retrospective analysis of 646 patients
10.4143/crt.2020.953 · 2021 · External reference
Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma
10.1136/gutjnl-2024-333368 · 2025 · External reference
Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer
10.1002/ijc.30760 · 2017 · External reference
Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated
10.1002/cncr.33135 · 2020 · External reference
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary carcinoma randomized trial
10.1001/jama.2012.7352 · ExternalCitation · doi-reference
Genome-derived ampullary adenocarcinoma classifier and postresection prognostication
10.1001/jamasurg.2024.3588 · ExternalCitation · doi-reference
Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study
10.1002/bjs.11555 · ExternalCitation · doi-reference
Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated
10.1002/cncr.33135 · ExternalCitation · doi-reference
Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer
10.1002/ijc.30760 · ExternalCitation · doi-reference
Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program
10.1002/jso.21374 · ExternalCitation · doi-reference
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater
10.1007/s12032-009-9351-4 · ExternalCitation · doi-reference
A randomised phase II study of oxaliplatin/fluorouracil (mFOLFOX) versus irinotecan/fluorouracil (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy
10.1016/j.ejca.2021.06.019 · ExternalCitation · doi-reference
Adjuvant chemo-radiotherapy in ampullary cancers
10.1016/j.ejso.2004.08.013 · ExternalCitation · doi-reference
Prospective evaluation of EUS versus CT scan for staging of ampullary carcinoma
10.1016/j.gie.2008.11.045 · ExternalCitation · doi-reference
Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma
10.1016/j.jamcollsurg.2014.07.665 · ExternalCitation · doi-reference
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
10.1016/s1470-2045(11)70301-1 · ExternalCitation · doi-reference
Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma
10.1038/bjc.2015.172 · ExternalCitation · doi-reference
The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma
10.1038/s41598-019-49179-w · ExternalCitation · doi-reference
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
10.1056/nejmoa0908721 · ExternalCitation · doi-reference
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy
10.1093/jjco/hyt237 · ExternalCitation · doi-reference
The gross anatomy and histology of the gallbladder, extrahepatic bile ducts, Vaterian system, and minor papilla
10.1097/00000478-198902000-00008 · ExternalCitation · doi-reference
The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater
10.1097/pas.0000000000000230 · ExternalCitation · doi-reference
Ampullary carcinoma--a separate clinical entity
10.1111/his.12324 · ExternalCitation · doi-reference
The 2019 WHO classification of tumours of the digestive system
10.1111/his.13975 · ExternalCitation · doi-reference
Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma
10.1136/gutjnl-2024-333368 · ExternalCitation · doi-reference
Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer
10.1159/000159624 · ExternalCitation · doi-reference
Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater
10.1177/030089161309900203 · ExternalCitation · doi-reference
Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma
10.1186/s12967-022-03473-w · ExternalCitation · doi-reference
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
10.1200/jco.2008.19.7145 · ExternalCitation · doi-reference
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater
10.1200/jco.2012.46.8868 · ExternalCitation · doi-reference
Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications
10.1309/ajcpctcuqsyi89yt · ExternalCitation · doi-reference
Ampullary cancer: an overview
10.14694/edbook_am.2014.34.112 · ExternalCitation · doi-reference
Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater
10.1620/tjem.231.21 · ExternalCitation · doi-reference
The diagnosis and treatment of ampullary cancer
10.3238/arztebl.m2023.0195 · ExternalCitation · doi-reference
Trends in incidence and management of cancer of the ampulla of Vater
10.3748/wjg.v20.i29.10144 · ExternalCitation · doi-reference
Adjuvant chemotherapy for resected ampulla of Vater carcinoma: retrospective analysis of 646 patients
10.4143/crt.2020.953 · ExternalCitation · doi-reference
Outcomes of palliative chemotherapy for ampulla of Vater adenocarcinoma: a multicenter cohort study
10.5009/gnl230164 · ExternalCitation · doi-reference
Ampullary adenocancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2023.0034 · ExternalCitation · doi-reference
